AU2002353972A1 - Lung cancer therapeutics and diagnostics - Google Patents

Lung cancer therapeutics and diagnostics

Info

Publication number
AU2002353972A1
AU2002353972A1 AU2002353972A AU2002353972A AU2002353972A1 AU 2002353972 A1 AU2002353972 A1 AU 2002353972A1 AU 2002353972 A AU2002353972 A AU 2002353972A AU 2002353972 A AU2002353972 A AU 2002353972A AU 2002353972 A1 AU2002353972 A1 AU 2002353972A1
Authority
AU
Australia
Prior art keywords
diagnostics
lung cancer
cancer therapeutics
therapeutics
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002353972A
Other languages
English (en)
Inventor
Jean S. Beebe
Kevin G. Coleman
Ethan Dmitrovsky
Thomas G. Turi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Pfizer Products Inc
Original Assignee
Dartmouth College
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, Pfizer Products Inc filed Critical Dartmouth College
Publication of AU2002353972A1 publication Critical patent/AU2002353972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2002353972A 2001-11-02 2002-11-02 Lung cancer therapeutics and diagnostics Abandoned AU2002353972A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33629801P 2001-11-02 2001-11-02
US33531701P 2001-11-02 2001-11-02
US33602401P 2001-11-02 2001-11-02
US60/335,317 2001-11-02
US60/336,024 2001-11-02
US60/336,298 2001-11-02
PCT/US2002/035149 WO2003040317A2 (en) 2001-11-02 2002-11-02 Lung cancer therapeutics and diagnostics

Publications (1)

Publication Number Publication Date
AU2002353972A1 true AU2002353972A1 (en) 2003-05-19

Family

ID=27407051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002353972A Abandoned AU2002353972A1 (en) 2001-11-02 2002-11-02 Lung cancer therapeutics and diagnostics

Country Status (5)

Country Link
US (1) US20030219768A1 (https=)
EP (1) EP1520032A4 (https=)
JP (1) JP2005531281A (https=)
AU (1) AU2002353972A1 (https=)
WO (1) WO2003040317A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
CA2527680A1 (en) * 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
US20070270504A1 (en) * 2003-06-20 2007-11-22 Avalon Pharmaceuticals, Inc. Identification of Therapeutic Agents Using Genetic Fingerprinting
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
CA2540280A1 (en) * 2003-10-07 2005-04-21 Entelos, Inc. Simulating patient-specific outcomes
US20060088862A1 (en) * 2004-09-30 2006-04-27 Nancy Lee Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods, and kits thereof
JP4580206B2 (ja) * 2004-10-08 2010-11-10 新日鉄ソリューションズ株式会社 化合物推定装置、化合物推定方法及びそのプログラム
EP1806581A4 (en) * 2004-10-28 2011-08-17 Seems Inc DISEASE DIAGNOSTIC SYSTEM
EP1829967A4 (en) * 2004-12-03 2008-04-23 Aichi Prefecture METHOD FOR DIAGNOSIS OF MALIGNEM LYMPHOMA AND ASSESSMENT OF THE FORECASTING THEREOF
EP3211093A1 (en) * 2005-04-14 2017-08-30 The Trustees of Boston University Diagnostic for lung disorders using class prediction
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2008039071A2 (en) * 2006-09-29 2008-04-03 Agendia B.V. High-throughput diagnostic testing using arrays
WO2009039190A1 (en) 2007-09-17 2009-03-26 Gene Express, Inc. Cancer risk biomarker
WO2009123990A1 (en) * 2008-03-31 2009-10-08 The University Of Toledo Cancer risk biomarker
US8652798B2 (en) * 2008-05-20 2014-02-18 The Regents Of The University Of California Analysis of ex vivo cells for disease state detection and therapeutic agent selection and monitoring
WO2010011642A2 (en) * 2008-07-21 2010-01-28 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
AU2011316986A1 (en) * 2010-10-20 2013-06-06 Rush University Medical Center Lung cancer tests
US9687467B2 (en) 2011-04-04 2017-06-27 Children's Medical Center Corporation Diagnosis and treatment of taxane-resistant cancers
US10338073B2 (en) 2011-04-14 2019-07-02 Raymond U. Osarogiagbon Lymph node specimen collection kit and method of pathological analysis for lung cancer diagnosis using such a kit
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
EP3080299B1 (en) 2013-12-09 2020-09-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
WO2017197335A1 (en) 2016-05-12 2017-11-16 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
CN110574414B (zh) 2016-12-27 2023-04-04 株式会社电装 用于微定位传感器通信的系统和方法
WO2021158713A1 (en) * 2020-02-03 2021-08-12 Tdl Innovations Llc Foam compositions for the treatment of cancer
CN118969273B (zh) * 2024-07-25 2025-02-28 常州贝格尔医学检验实验室有限公司 一种靶向用药方案的评价方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509707A (ja) * 1998-03-31 2002-04-02 ジェンザイム・コーポレーション 肺腫瘍細胞を同定するための組成物および方法
AU4651500A (en) * 1999-04-23 2000-11-10 Corixa Corporation Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma
EP1242598A2 (en) * 1999-12-30 2002-09-25 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Also Published As

Publication number Publication date
JP2005531281A (ja) 2005-10-20
WO2003040317A2 (en) 2003-05-15
EP1520032A2 (en) 2005-04-06
WO2003040317A8 (en) 2005-02-03
EP1520032A4 (en) 2007-07-18
US20030219768A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
WO2003040317A8 (en) Lung cancer therapeutics and diagnostics
AU2002344208A1 (en) Molecules for diagnostics and therapeutics
WO2002089880A8 (en) Inhalers
AU2001274944A1 (en) Method and assembly for lung volume reduction
AU2002246378A1 (en) Respirator
AU2002324677A1 (en) Removable lung reduction devices, systems, and methods
AUPR395801A0 (en) Antibodies against cancer
AU2002343151A1 (en) Perceptual noise substitution
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2002327860A1 (en) Diagnostic methods
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2002359694A1 (en) Compounds and methods
AU2002364901A1 (en) Object decontaminator
AU2002305913A1 (en) Molecules for diagnostics and therapeutics
AU2002321560A1 (en) Inhaler
AU2002314057A1 (en) Inhaler
AU2002301078B2 (en) An Inhaler
AU2002355220A1 (en) Cancer diagnostics
AU2002358888A1 (en) Lung simulator
AU2002310815A1 (en) Inhalers
AUPR772501A0 (en) An inhaler
AU2002328673A1 (en) An inhaler
AUPR776701A0 (en) An inhaler
AUPR776601A0 (en) An inhaler
AU2002221493A1 (en) Combined window

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase